Roth Capital Upgrades CymaBay Therapeutic (CBAY) to Buy

Roth Capital analyst Yasmeen Rahimi upgraded CymaBay Therapeutic (NASDAQ: CBAY) from Neutral to Buy with a price target of $15.00.

The analyst comments "Yesterday afternoon, CBAY disclosed in its 1Q20 earnings update that an independent expert panel concluded that seladelpar did not induce any clinical, biochemical, or histological liver injury in its Phase 2b NASH study that demolished CBAY shares in Nov. 2019. In this report, we summarize why we upgrade our rating from Neutral to Buy as we believe seladelpar has been revived and will stand stronger than ever."

For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.

Shares of CymaBay Therapeutic closed at $4.83 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Keefe, Bruyette & Woods Upgrades Nayax (NYAX) to Outperform
• Wolfe Research Upgrades Abbvie (ABBV) to Outperform